AU2023262641A1 - Treatment of cervical dystonia - Google Patents

Treatment of cervical dystonia Download PDF

Info

Publication number
AU2023262641A1
AU2023262641A1 AU2023262641A AU2023262641A AU2023262641A1 AU 2023262641 A1 AU2023262641 A1 AU 2023262641A1 AU 2023262641 A AU2023262641 A AU 2023262641A AU 2023262641 A AU2023262641 A AU 2023262641A AU 2023262641 A1 AU2023262641 A1 AU 2023262641A1
Authority
AU
Australia
Prior art keywords
modified bont
processus
bont
capitis
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023262641A
Other languages
English (en)
Inventor
Nicolae GRIGORE
Laurent PONS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Biopharm Ltd
Original Assignee
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Biopharm Ltd filed Critical Ipsen Biopharm Ltd
Publication of AU2023262641A1 publication Critical patent/AU2023262641A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2023262641A 2022-04-29 2023-03-23 Treatment of cervical dystonia Pending AU2023262641A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2206353.1A GB202206353D0 (en) 2022-04-29 2022-04-29 Treatment of cervical dystonia
GB2206353.1 2022-04-29
PCT/GB2023/050742 WO2023209326A1 (en) 2022-04-29 2023-03-23 Treatment of cervical dystonia

Publications (1)

Publication Number Publication Date
AU2023262641A1 true AU2023262641A1 (en) 2024-10-10

Family

ID=81943814

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023262641A Pending AU2023262641A1 (en) 2022-04-29 2023-03-23 Treatment of cervical dystonia

Country Status (9)

Country Link
US (1) US20250302928A1 (https=)
EP (1) EP4514378A1 (https=)
JP (1) JP2025514275A (https=)
KR (1) KR20250004869A (https=)
CN (1) CN119110728A (https=)
AU (1) AU2023262641A1 (https=)
CA (1) CA3245899A1 (https=)
GB (1) GB202206353D0 (https=)
WO (1) WO2023209326A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025231403A1 (en) * 2024-05-03 2025-11-06 Revivity Pharma Corporation Methods of administering and manufacturing toxic compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
ES2369558T3 (es) 2005-09-19 2011-12-01 Allergan, Inc. Toxinas clostridiales y toxinas clostridiales activables.
CA2758274C (en) 2009-04-14 2018-04-10 Mcw Research Foundation, Inc. Engineered botulinum neurotoxin
US8853360B2 (en) 2010-06-23 2014-10-07 Wisconsin Alumni Research Foundation Engineered botulinum neurotoxin C1 with selective substrate specificity
EP3162894B1 (en) 2011-05-19 2024-01-10 Ipsen Bioinnovation Limited Methods for the manufacture of proteolytically processed polypeptides
SG10201606666XA (en) 2012-05-30 2016-09-29 Harvard College Engineered Botulinum Neurotoxin
WO2014079495A1 (en) 2012-11-21 2014-05-30 Syntaxin Limited Methods for the manufacture of proteolytically processed polypeptides
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
PT3274364T (pt) 2015-03-26 2021-11-05 Harvard College Neurotoxina botulínica manipulada
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3481852B1 (en) 2016-07-08 2022-12-07 Children's Medical Center Corporation A novel botulinum neurotoxin and its derivatives
TWI810228B (zh) * 2017-12-20 2023-08-01 英商艾普森生物製藥有限公司 自主神經系統障礙之治療
JP2024534384A (ja) * 2021-09-16 2024-09-20 イプセン バイオファーム リミテッド 頸部ジストニアを治療する用途の修飾ＢｏＮＴ／Ａ

Also Published As

Publication number Publication date
GB202206353D0 (en) 2022-06-15
JP2025514275A (ja) 2025-05-02
CA3245899A1 (en) 2023-11-02
KR20250004869A (ko) 2025-01-08
CN119110728A (zh) 2024-12-10
WO2023209326A1 (en) 2023-11-02
US20250302928A1 (en) 2025-10-02
EP4514378A1 (en) 2025-03-05

Similar Documents

Publication Publication Date Title
EP4401759B1 (en) Modified bont/a for use in the treatment of cervical dystonia
US20250179461A1 (en) Modified Bont/A for Use in the Treatment of a Disorder Affecting an Eyelid Muscle of a Subject
US20250302928A1 (en) Treatment of cervical dystonia
US20250213662A1 (en) Bont/a for use in treating a facial dystonia
US20250177278A1 (en) Treatment of upper facial lines
WO2025093844A1 (en) Use of chimeric botulinum toxin a for treating blepharospasm and hemifacial spasm
EP4514379A1 (en) Treatment of limb spasticity
WO2025093845A1 (en) Use of high dose chimeric botulinum toxin a for the treatment of upper facial lines
HK40114696A (zh) 颈肌张力障碍的治疗
HK40114374A (zh) 修饰的bont/a用於颈肌张力障碍的治疗
HK40118896A (zh) 上面部纹的治疗